Entry › For parents · Last reviewed 2026-05-16
For parents
What you should know before a gender clinic admits your child to a pathway with irreversible consequences.
Read this first
The Dutch Protocol — developed in the Netherlands, applied internationally — has since 2020 been critically reassessed in several countries. NICE (UK, 2020) rated the evidence for puberty blockers "very low certainty" (source), SBU (Sweden, 2022) found the evidence insufficient (source) and the Cass Review (UK, 2024) found insufficient and/or inconsistent evidence on psychological and psychosocial effects (source). In March 2024 NHS England decided that puberty blockers are no longer routinely available for under-18s (source). The Netherlands continues the approach: on 30 June 2026 the Gezondheidsraad rated the evidence "low to very low" but saw no reason to organise care differently (source). Parents who consider entrusting their child to this pathway have a right to that information — not as opinion, but as fact.
What the protocol entails
- Puberty blockers (GnRHa) from ~12 years old. Presented as a way to buy time to think; the Cass Review found no evidence that puberty blockers buy time to think. In Dutch and UK studies 93–98% of those who started puberty blockers went on to cross-sex hormones (source). See the three phases.
- Cross-sex hormones from ~16 years old. Effects on fertility, sexual function and bone and cardiovascular health are partly irreversible, partly unknown.
- Surgery from 18 years old. Fully irreversible. WPATH SOC-8 removed age limits after publication.
Questions to ask before you consent
- Which independent (non-AUMC) systematic review underpins the treatment of my child?
- Has comorbidity (autism, depression, trauma, eating disorder) been systematically investigated? In a Dutch study of 204 children and adolescents referred to the Amsterdam clinic, 7.8% had an ASD diagnosis (source); the Cass Review's pooled figure across nine countries is 9% (range 0–26%) (source). See exclusion criteria.
- What specific information will my child receive about loss of fertility, sexual function and the irreversible character of CSH and surgery? See informed consent.
- What is the clinician's position on the Cass Review, SBU and COHERE? Are these reports discussed — or waved away?
- Which psychosocial interventions (talk or family therapy, autism assessment, trauma treatment) have been offered before hormones are considered? The Cass Review recommends standard evidence-based psychological and psychopharmacological treatment of associated distress and co-occurring conditions (recommendation 3) (source).
- How long and with which outcome measures will my child be followed after treatment starts? The last assessment in de Vries 2014 took place at least one year after gender reassignment surgery, at a mean age of 20.7 years (source). See follow-up.
What to be prepared for
- The "transition or suicide" framing: ask which research supports the claim that treatment prevents suicide. Whoever pressures you to consent quickly under this framing should be able to name that source. See WPATH Files.
- "Desistance no longer exists" is sometimes claimed. Follow-up studies of children referred before puberty found that most no longer had gender dysphoria in adolescence: in Wallien and Cohen-Kettenis (2008), of 77 referred children 43% no longer had gender dysphoria, 27% still had it and 30% could not be traced (source). The Olson 2022 figures concern an already socially transitioned subgroup — not a general figure. See desistance research.
- Social transition is not "neutral". The Cass Review found that those who had socially transitioned at an earlier age were more likely to proceed to a medical pathway, but writes that it is not possible to know from these studies whether social transition was the cause (source).
See also
- FAQ — answers to commonly recurring questions.
- International comparison — what 10 countries do now.
- Glossary — explanation of terms.
- For clinicians · For journalists
- Contact for specific questions.